|
|
Дата |
---|
31.07.2025 |
29.07.2025 |
28.07.2025 |
25.07.2025 |
21.07.2025 |
16.07.2025 |
15.07.2025 |
09.07.2025 |
07.07.2025 |
30.06.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.0971
|
|
0.15
|
0.15
|
0.15
|
0.15
|
|
|
|
1.00
|
0.075
|
|
0.18
|
0.18
|
0.18
|
0.18
|
|
|
37.08
|
4.00
|
0.085
|
|
0.19
|
0.19
|
0.19
|
0.19
|
|
|
|
1.00
|
0.222
|
|
0.11
|
0.11
|
0.21
|
0.1999
|
|
|
1 010.40
|
6.00
|
0.035
|
|
0.0971
|
0.0971
|
0.0971
|
0.0971
|
|
|
|
1.00
|
|
|
0.0999
|
0.0999
|
0.0999
|
0.0999
|
|
|
|
1.00
|
0.035
|
|
0.0971
|
0.0971
|
0.0971
|
0.0971
|
|
|
|
1.00
|
0.0865
|
|
0.1096
|
0.1096
|
0.1096
|
0.1096
|
|
|
|
1.00
|
0.05
|
0.288
|
0.0902
|
0.0902
|
0.0902
|
0.0902
|
|
|
|
1.00
|
0.035
|
0.288
|
0.1051
|
0.1051
|
0.1051
|
0.1051
|
|
|
134.58
|
2.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть